Cytokinetics (CYTK) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$67.7M

Revenue (quarter)

$28.6M

Revenue growth (year over year)

−57.13%

Gross profit (trailing twelve months)

$63.5M

Gross margin

93.87%

Net income (trailing twelve months)

−$894.0M

Net income (quarter)

−$198.8M

Net income growth (year over year)

−47.92%

Net margin

−1321.12%

Return on equity

—

EPS (trailing twelve months)

−$7.22

Book value per share

−$1.25

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

109.01%

Payout ratio

—

Dividend yield

—

Company profile

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

• Is Cytokinetics (CYTK) profitable?

  No. Cytokinetics reported a net loss of $894.0M over the trailing twelve months.

• How much revenue does Cytokinetics (CYTK) make?

  Cytokinetics generated $67.7M in revenue over the trailing twelve months, down 57.13% year over year.

• How do I buy stock in Cytokinetics (CYTK)?

  CYTK trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.